Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	14.85B
Revenue (ttm)	15.85B
Net Income (ttm)	-559.00M
Shares Out	1.12B
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	5.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,466,564
Open	12.81
Previous Close	13.01
Day's Range	12.80 - 13.30
52-Week Range	7.09 - 14.47
Beta	1.06
Analysts	Buy
Price Target	13.78 (+4.0%)
Earnings Date	May 8, 2024

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 37,851
• Stock Exchange: NYSE
• Ticker Symbol: TEVA

Financial Performance

In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is $13.78, which is an increase of 4.00% from the latest price.

Price Target

$13.78

(4.00% upside)

Analyst Consensus: Buy